FDA issues warning letter to Sanofi over its Genzyme facility, citing process deviations, equipment issues, and quality oversight lapses.
Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses
Where Today's News Shapes Tomorrow
February 15, 2026
Headlines
